zolmitriptan has been researched along with cp 122288 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrett, V; Brockwell, M; Cambridge, D; Farrant, DR; Foster, C; Giles, H; Glen, RC; Hill, AP; Hobbs, H; Honey, A; Jandu, KS; Martin, GR; Salmon, J; Selwood, DL; Smith, D; Woollard, P | 1 |
1 other study(ies) available for zolmitriptan and cp 122288
| Article | Year |
|---|---|
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
Topics: Administration, Oral; Animals; Binding, Competitive; Biological Availability; Brain; Capillary Permeability; Cattle; CHO Cells; Cricetinae; Ear; Electric Stimulation; Guinea Pigs; Humans; In Vitro Techniques; Indoles; Male; Migraine Disorders; Models, Molecular; Oxazoles; Rabbits; Rats; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Regional Blood Flow; Serotonin Receptor Agonists; Serum Albumin, Bovine; Structure-Activity Relationship; Trigeminal Ganglion; Vasoconstrictor Agents | 2001 |